Welcome to our dedicated page for I-Mab SEC filings (Ticker: IMAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing I-Mab’s immuno-oncology disclosures is no small task. Each study update, milestone payment, or safety signal can span dozens of pages, leaving investors hunting for the data that moves the stock. That’s why this page brings every filing—from the I-Mab annual report 10-K simplified to the I-Mab quarterly earnings report 10-Q filing—into one searchable hub. Stock Titan’s AI continuously reviews new documents, turning dense text into plain-English bullet points so you get I-Mab SEC filings explained simply.
Want to spot insider sentiment? Our dashboard highlights I-Mab insider trading Form 4 transactions within minutes of release and sends alerts on I-Mab Form 4 insider transactions real-time. Need fast context on pipeline shifts? The platform tags each I-Mab 8-K material events explained, linking drug-specific updates to trial registries. For capital structure or board changes, the I-Mab proxy statement executive compensation section breaks down pay packages, option grants, and voting matters you’ll actually care about.
By understanding I-Mab SEC documents with AI, professionals can quickly run I-Mab earnings report filing analysis, monitor I-Mab executive stock transactions Form 4, and track cash runway all in one place.
- AI-powered summaries that surface trial catalysts and risk factors
- Real-time EDGAR feeds for every form type
- Clickable tables that compare quarter-over-quarter R&D spend
Skip the scroll; access the insights that drive decisions before the market prices them in.
I-Mab outlined a strategic shift to a biotech platform model using focused subsidiaries and plans to change its name to NovaBridge Biosciences, subject to shareholder approval at an EGM on October 24, 2025. The company formed Visara, Inc. and agreed to a Series A financing in which it will purchase 35 million Visara preferred shares for about
At closing, I-Mab will pay AffaMed
I-Mab also announced its intention to pursue a dual primary listing on the HKEX via an initial public offering, subject to market and regulatory approvals. Kyler Lei was appointed Chief Financial Officer effective immediately, with Joseph Skelton transitioning to an advisory role.
I-Mab (IMAB) reports follow-up details on its Greater China divestiture and related equity interests in TJBio Hangzhou. The company completed an equity transfer that converted a former wholly owned subsidiary into an affiliate and received contingent consideration of up to
I-Mab records an estimated equity value for TJBio Hangzhou of
FAQ
What is the current stock price of I-Mab (IMAB)?
What is the market cap of I-Mab (IMAB)?
